Tumor suppressor p53 gene abnormalities are among the most common molecular defects in cancers causing tumor progression, treatment resistance and immune suppression.

MultiVir’s Ad-p53 product candidates deliver normal p53 genes into tumors to restore their tumor suppressor functions which include inhibition of tumor growth and the activation of anti-tumor immune responses.

The Ad-p53 Dendritic Cell Vaccine (Ad-p53 DCV) is an investigational immune stimulating therapy designed to activate the immune system to attack tumor cells that express high levels of p53 which occurs in many types of cancer.